DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Thursday, 7 April 2016

Pratibha Pilgaonkar CEO at RUBICON RESEARCH LTD

Pratibha Pilgaonkar.

 Pratibha Pilgaonkar  


 Rubicon Research

Ms. Pratibha Pilgaonkar B.Sc. (Chem), B.Sc. (Tech) UICT, India
Chief Executive Officer, Board of Directors, Scientific Advisory Board

Mrs. Pilgaonkar is unique in that she combines Innovative and technical leadership with a vision to establish various R&D organizations of Global significance. She started her career in Burroughs Welcome (GlaxoSmithKline) in 1977 as a formulation development scientist. As head of product development at Ciba Geigy (Novartis), she pioneered formulation development outsourcing efforts from India in 1991 thus-laying the foundation of current Sandoz Research Center in Mumbai. As Vice President, R & D she played a major role in development of Sun Pharma’s Advanced Research Center – (SPARC), Mumbai and was instrumental in successful technology transfer of several products to the Caraco plant in Michigan.

This stellar professional career path has enriched the lives of many budding technocrats and entrepreneurs as Mrs. Pilgaonkar has mentored them for “out of the box” thinking. Mrs. Pilgaonkar has numerous patents and publications to her credit and has developed platform technologies in the area of controlled release, gastric retention, orally disintegrating tablets, tablet for suspension, taste masking and pediatric formulations.

Her alma mater is the prestigious UICT, (University Institute of Chemical Technology) where she graduated in Chemical Technology in 1976. In her spare time, Mrs. Pilgaonkar enjoys gardening, listening to Indian Classical and Folk Music and taking short trips to the countryside.

 Rubicon Research





Wilson College

B Sc, Chemistry

Pratibha Pilgaonkar serves as the Chief Executive Officer of Rubicon Research Private Limited. Ms. Pilgaonkar served as Vice-President of Product Development at Sun Pharmaceutical Industries Limited. Ms. Pilgaonkar served as Head of Product Development at Hindustan Ciba Geigy Limited (Novartis) and Pharmaceutical Development Function, Burroughs Wellcome India Limited. Ms. Pilgaonkar has an international reputation for creating networks of researchers and building effective and viable knowledge-based organizations. Ms. Pilgaonkar has a B.Sc. (Tech.) in Pharmaceutical Sciences from Bombay University's prestigious Institute of Chemical Technology.


Rubicon inaugurates the first CTS facility in India
Our News Bureau - Mumbai

Dr Pratibha Pilgaonkar
inaugurates the seminar
Rubicon Research, a product development and drug delivery company, held a seminar on 'Clinical trial supplies-Challenges and opportunities' to mark the inauguration of its cGMP Clinical Trial Supplies (CTS) facility at Ambernath (50 kms from Mumbai international airport) on August 19,2008. The event comprised of scientific and business sessions delivered by various global industry leaders.
Key speakers at the event were Professor Clive Wilson, University of Strathclyde, Glasgow, Scotland, who spoke about the value and critical nature of clinical trials; Gopal Pai, Neuromolecular Pharma, who discussed the various outsourcing strategies in CTS; K V Subramanian, President and CEO, Reliance Life sciences, who addressed the global issues plaguing the biotech and pharma industry; and Nitin Deshmukh, CEO-Private Equity, Kotak Mahindra Bank, who provided an insight into the growth of Indian biotech industry in 2008.
Rubicon's CTS facility can accelerate the vertical integration Rubicon's business model in the area of formulation development, allowing the company to speed up product development lead times from product development to pivotal batches manufacturing required for product registration. It will also allow submission of CMC data for any NDA/sNDA/ ANDA applications, thus eliminating the need of technology transfer to other companies thereby protecting the intellectual property. Clinical trials supplies can be organised for multicentric trials in a structured way from this facility.
Earmarked for future expansion, the facility has been built in consultation with a US regulatory agency and is designed to meet US FDA/MHRA regulatory norms. This is a first of its kind facility in India, offering the entire gamut of clinical supplies, from clinical manufacturing to clinical trial material (CTM) depot. Through this facility, Rubicon also would extend expertise and services for its clients in the current core areas of formulation development, analytical development, stability studies and technology transfer.
Other than being a stop shop for clinical supplies is its flexibility to manufacture batches from development quantities (less than 5 kg batch size) to 1,00,000 units (120 kg batch size) and its containment suite to handle NCEs and high potency compounds along with packaging capabilities to accommodate complex CTS requirements like blinding, randomisation, patient packs.

Ms. Pratibha Pilgaonkar, Director & CEO of Rubicon Research launching my book in their office on 09th Sep.